• Home
  • About
  • Portfolio
  • Meet the Team
  • News
  • Contact
  • Investor Portal

  • info@chv.vc

  • 50 Braintree Hill Office Park Suite 301 Braintree, MA 02184

Home / News / PanTher Therapeutics

PanTher Therapeutics


PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer
  • October 15, 2021
  • -
  • PanTher Therapeutics
PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia; Announces Appointment of Chief Medical Officer; Establishes Clinical Advisory Board
  • August 4, 2021
  • -
  • PanTher Therapeutics
PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer
  • June 17, 2021
  • -
  • PanTher Therapeutics

Let’s Connect.

Contact Us
https://chv.vc/wp-content/uploads/2020/08/footer-logo.png

Sitemap

  • Home
  • About
  • Portfolio
  • Meet the Team
  • News
  • Contact
  • Investor Portal

About

Catalyst Health Ventures (CHV) is a venture capital fund investing in transformative medical technologies addressing global unmet needs.

Contact

  • info@chv.vc

Boston Web Design by GoingClear